Clinical Trial of Trelagliptin Succinate Tablets in the Treatment of Type 2 Diabetes
Status:
Completed
Trial end date:
2020-12-28
Target enrollment:
Participant gender:
Summary
The trial used a randomized, double-blind, placebo-controlled, superior-effect design,
multicenter clinical study.
The trial was divided into a test group and a placebo group,the two groups were randomized in
a 1:1 ratio and planned to enroll 240 patients with type 2 diabetes. After 2 weeks of
screening, all subjects entered the treatment period,which was 24 weeks, and 1 week period of
follow-up.